Basal forebrain volume and concurrent hallucinations and mild cognitive impairment in

Parkinson's disease

Sabrina M. Adamo, MA[1,2], Vaishali Mutreja, MSc [1], Marta Statucka, PhD[1], Batu Kaya, MSc[1],

Taylor W. Schmitz, PhD[3], Anthony C. Ruocco, PhD[2], Melanie Cohn, PhD[1,2]

[1]Krembil Brain Institute, Toronto Western Hospital UHN, Toronto, Ontario, Canada; [2]Graduate

Department of Psychological Clinical Science, University of Toronto, Ontario, Canada;

[3]Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario,

Canada

ORCiDs: Adamo, S: https://orcid.org/0000-0002-6105-9984; Mutreja, V: https://orcid.org/0000-

0001-6909-2028; Statucka, M: https://orcid.org/0000-0003-0241-2992; Kaya, B:

https://orcid.org/0000-0003-0484-1467; Schmitz, TW: https://orcid.org/0000-0003-0585-7524;

Ruocco, A: https://orcid.org/0000-0002-1942-7181; Cohn, M: https://orcid.org/0000-0003-2921-

7505

Corresponding author: Dr. Melanie Cohn, melanie.cohn@uhn.ca

Address: Neuropsychology Clinic 4F-409, Toronto Western Hospital UHN, 399 Bathurst Street,

Toronto, Ontario, Canada, M5T 2S8

Word count: 3716

Abstract: 250 words

References: 50

Running title: Basal forebrain in PD

Keywords: psychosis, cholinergic nuclei, cognitive decline, structural MRI, non-motor

symptoms, voxel-based morphometry

ABSTRACT

Background

Visual hallucinations (VH) and mild cognitive impairment (MCI) often co-occur in Parkinson's

Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF)

atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to

their co-occurrence, and whether this relationship is specific to the nucleus basalis of Meynert

(Ch4 & Ch4p) or extends to other BF nuclei (Ch1-2 & Ch3).

Objectives

To bridge the literature on MCI, VH, and the BF by examining associations between total and

subregional BF volumes with VH, MCI, and concurrent symptomology.

Methods

We used clinical and structural MRI data in PD patients (n=296), evaluated prior to deep brain

stimulation. PD-MCI was identified in 61% of patients, VH in 25%, and symptoms co-occurred

in 21% of the sample. We conducted logistic regressions to examine the relationships between

BF volumes (total BF, Ch1-2, Ch3, Ch4, and Ch4p) with MCI, VH, and their combination,

accounting for potential confounders (age, sex, LEDD, dopamine agonist, and anticholinergic

medications).

Results

Total BF, Ch1-2 and Ch4 volumes are negatively associated with the likelihood of PD-MCI, but

not VH when the other symptom type is not considered. When both symptoms are considered,

Total BF and Ch4 volumes are negatively related to the co-occurrence of MCI and VH relative to

neither symptom.

Conclusions

Our data support the "cholinergic phenotype" in that BF atrophy, including Ch4, is associated

with concomitant MCI and VH. Ch1-2 volume is further associated with MCI, which is

interesting given its temporal lobe projections.

Non-motor symptoms such as visual hallucinations (VH) and mild cognitive impairment

(MCI) are common in Parkinson's disease (PD) [1,2]. Each symptom is a risk factor for the other

and for the development of dementia, and their combination may reflect a malignant course

associated with a rapid progression towards dementia [3]. While the relationship between VH

and MCI is not yet fully understood, cholinergic depletion stemming from basal forebrain (BF)

degeneration may be a key contributor to each symptom. Pasquini et al. [4] proposed a

"cholinergic phenotype" comprising the presence of MCI, VH, as well as other symptoms (e.g.,

gait problems, sleep disturbances, and olfactory impairment). Importantly, this proposal is based

on their review of neuroimaging (PET, SPECT, & MRI) and post-mortem pathology studies

showing cholinergic and BF alterations in PD-VH and PD-MCI in isolation, rather than in

patients with concomitant symptomatology, as studies rarely report the co-occurrence of these

symptoms. Thus, it remains uncertain whether BF alterations and associated cholinergic loss are

preferentially associated with one symptom type or with concomitant symptoms, as their

frequent co-occurrence may have created a confounding or third variable problem in previous

research.

The BF, which is the main sources of acetylcholine to the brain, is comprised of multiple

cholinergic nuclei. Ch1-2 project mainly to the hippocampi, Ch3 projects to the olfactory bulb

and entorhinal cortex, and the nucleus basalis of Meynert (NBM), which can be segmented into

anterior (Ch4) and posterior (Ch4p) regions, projects to the neocortex and basolateral amygdala

[5,6]. NBM alterations are associated with VH [7] and with cognitive decline [8,9] in PD. In

addition, reduced white matter integrity of BF projections has been shown in PD-VH compared

with PD-noVH and controls groups [10], and in the NBM of PD-MCI patients compared with

PD patients with intact cognition [8]. Post-mortem pathology studies showed a buildup of Lewy

bodies in the NBM of PD patients with well-formed VH as well as with PD dementia [11]. To

date, there is limited research on the other anterior BF nuclei (Ch1-2-3), and of those limited

studies, the reported results either pertain to Ch1-2 alone or in combination with Ch3, while Ch3

has not been assessed on its own [6]. Specifically, only three studies examine these anterior BF

nuclei in PD [7,9,12]; none of which report volumetric loss in PD-MCI or PD-VH versus their

cognitively intact or non-hallucinating counterparts [7,9], and only one study found differences

in Ch1-2-3 and Ch4 between PD patients and healthy controls [12], but with no report of whether

patients presented with VH or MCI.

Importantly, no studies have tested the cholinergic phenotype proposal directly by

investigating BF structural integrity in patients with concomitant PD-MCI and VH. Furthermore,

research on individual symptom type focuses primarily on the Ch4 within a single early PD

dataset (i.e., Parkinson's Progression Markers Initiative; [7–9], but see [12,13] for other cohorts).

This literature is further muddied by the confounding effects of medications [levodopa,

dopamine agonists (DA), and anticholinergic medications], which may, at high dose, promote or

exacerbate both cognitive [14,15] and VH symptoms [15,16].

The aim of this study is to test the cholinergic phenotype proposed by Pasquini et al. [4],

and by doing so, bridge the two bodies of literature on VH, MCI, and the BF. Specifically, our

goal is to examine whether the BF is a common neural substrate of PD-VH and PD-MCI while

accounting for the confounding effects of demographic characteristics and both dopaminergic

and anticholinergic pharmacotherapy. To achieve this, we performed a retrospective clinical

chart review consisting of data from a multidisciplinary assessment (neuropsychology,

neurology) and structural MRI completed prior to Deep Brain Stimulation (DBS). First, we

hypothesize that total BF volume, and specifically the NBM, is associated with MCI as well as

VH when examined in isolation, as suggested by the literature on each symptom type. Second,

based on the cholinergic phenotype proposal suggesting that VH and MCI have a compounding

effect, we hypothesize that smaller total BF and NBM volumes are associated with concomitant

symptoms relative to groups presenting with one symptom or neither. As the other BF nuclei

(Ch1-2, Ch3) have seldom been investigated [6], we explore whether similar patterns are found

with these regions.

METHODS

Participants

We conducted a chart review of PD patients who underwent multidisciplinary

assessments and 3T MRI prior to DBS at the Toronto Western Hospital between January 2007

and August 2021. Exclusion criteria were: poor imaging quality, > six-month gap between the

neuropsychological assessment and MRI, age < 40, neurological disorders other than PD (e.g.

stroke, epilepsy, moderate to severe traumatic brain injury), severe mental illness (schizophrenia,

personality disorders), severe scores on depression scales [Beck Depression Inventory-II (BDI-

II) > 28, or Geriatric Depression Scale (GDS) > 19)]; [17,18], PD dementia based on Emre et al.

2007 criteria [19] and dementia with Lewy bodies based on McKeith et al. 2017 criteria [20],

limited English fluency, level I neuropsychological assessment [21], and missing VH data. A

total of 296 people met inclusion criteria.

Sample characteristics

Demographic variables included age, sex, and years of education. Clinical variables

pertaining to pharmacotherapy included levodopa equivalent daily dose (LEDD) [22], whether

patients took DA (yes/no), and whether they are prescribed high levels of anticholinergic

medications (i.e., score $\geq$ 3 on the Anticholinergic Cognitive Burden Scale (ACB) [23]). Specific

DA and anticholinergic medications, including antipsychotics and cognitive enhancers, are

reported in Table S1. Additional clinical variables included disease duration (based on diagnosis

date), motor symptom severity ON and OFF [Movement Disorders Society-Unified Parkinson's

Disease Rating Scale Part III (MDS-UPDRS-III)] [24], and percent levodopa response [(OFF–

ON)/OFF*100%]. UPDRS-III [25] scores were converted to MDS-UPDRS-III scores for 218

patients using a validated transformation method [26]. OFF scores were not available for seven

patients who did not complete a levodopa challenge within six months of the MRI or

neuropsychological testing.

Visual Hallucination Status

All patients completed a semi-structured clinical interview alone (14%) or with their

care-partners (86%) during which they were asked whether they experience minor VH (feelings

of presence, passage illusions, visual misperceptions), well-formed hallucinations or delusions,

and whether they retained insight vis-à-vis these experiences. These open-ended descriptions

were summarized in the clinical neuropsychological reports and the presence and severity of VH

were coded on the MDS-UPDRS [24] item 1.2 by two independent raters with high interrater

reliability (Cohen's Kappa>0.8), and discrepancies were resolved by consensus [22] This item

ranges from 0-4 where 0=absence of hallucinations, 1=minor hallucinations, 2=well-formed

hallucinations with preserved insight, 3=well-formed hallucinations with loss of insight, and

4=delusions. Scores were then binarized (yes/no), and patients with a score > 0 were included in

the VH group. More fine-grained severity ratings and subtypes of minor hallucinations are

reported in Table S2.

PD-MCI status

Cognitive diagnoses (PD-MCI versus intact cognition) were based on a level II neuropsychological assessment [21] and reached via consensus by licenced neuropsychologists (M.S. and M.C.) based on the presence of subjective cognitive decline, preserved independence with instrumental activities of daily living, and performance falling 1.5 SD below normative data on at least two independent neuropsychological tests. Visuoperceptual and spatial measures included the Benton Judgement of Line Orientation [27], Object Decision and Silhouette subtests from the Visual Object and Space Perception battery [28], and the Rey-Osterrieth (Rey-O) Figure Copy test [29]. Language tests comprised of the Boston Naming Test [30], Vocabulary subtest from the Wechsler Abbreviated Scale of Intelligence (WASI or WASI-II) [31,32], and the Category Verbal Fluency subtest from the Delis-Kaplan Executive Function System (D-KEFS) [33]. Memory tests included the California Verbal Learning Test-II [34], Logical Memory I and II subtests from the Wechsler Memory Scale-III (WMS-III) [35], and the Rey-O recognition test [29]. Attention and processing speed were assessed using the Trail Making Test-A (TMT-A) [36], D-KEFS Stroop colour and reading speed [33], and the Digit Span subtest from the WMS-III [35]. Lastly, executive functioning was assessed using the D-KEFS Letter and Switching Verbal Fluency, D-KEFS Stroop interference and switching [33], TMT-B [36], Wisconsin Card Sorting Test [37], Matrix Reasoning subtest from the WASI or WASI-II [31,32], and the Conditional Associative Learning Test [38]. The BDI-II [17] or GDS [18] questionnaires were also collected and used for the exclusion criteria. MCI subtypes and cognitive domains affected are described in Table S3.

MRI acquisition and preprocessing

T1-weighted spoiled gradient recalled echo (SPGR) structural MRI scans were acquired

on a 3T Signa MR system (GE Medical Systems, Milwaukee, WI). Images were resliced to

1x1x1mm voxel dimensions due to some variability in acquisition parameters (voxels acquired at

<1mm^3, see Table S4). MRIQC [39] was used for visual inspection. A voxel-based morphometry

pipeline previously used in Alzheimer's disease [40,41] was implemented in SPM12

(http://www.fil.ion.ucl.ac.uk/spm) and MATLAB 2018a. First, images were bias-corrected to

adjust for inhomogeneity and aligned into anterior/posterior commissure space before being

affine co-registered to the Montreal Neurological Institute (MNI) template space. Grey matter

(GM), white matter, cerebrospinal fluid, and total intracranial volume (TIV) segmentations were

then generated on the T1 images and moved to a study-specific template using DARTEL. A

study-specific template was used to minimize the geodesic distance from each subject to the

population mean [42]. Non-linear modulation of GM images was done using the CAT12 toolbox,

resulting in voxel-based indices of GM volume. There was no spatial smoothing applied to the

volumes. Scans with poor imaging quality based on visual inspection or ones that failed CAT12

quality pipeline (e.g., homogeneity outliers) were excluded (n=4). Four bilateral BF ROIs (Ch1-

2, Ch3, Ch4, Ch4p) reflecting different BF subregions derived from histological post-mortem

studies [43] were segmented using a threshold of 50% (which is optimal for BF volume

extraction [44]). As these ROIs are in MNI space, they were warped to the DARTEL study-

specific template. The four ROIs were combined into a single volumetric mask to generate a fifth

ROI representing total BF volume. These five ROIs were used to extract GM volumetric data

consisting of the sum of the total intensity of voxels within each ROI adjusted for the number of

voxels. Each volume was corrected for head size using TIV as a proxy by applying a residual

approach (i.e., residuals from linear regressions), as recommended by Wang et al. [45] see Ray et

al., [9] for similar approach applied to BF volumes in PD].

Statistical analyses

Demographic and clinical characteristics were compared between cognitive and VH

status groups separately, using Mann-Whitney U (due to non-normality of some variables on the

Kolmogorov-Smirnov test), and Chi-square tests. Rank-biserial correlations r and OR with

95%CI were reported as effect sizes. The relationships between the Total BF volume, VH and

MCI were examined initially using Mann-Whitney U, followed by logistic regressions in which

five covariates were added to account for potential confounds. These included age and sex, given

their inclusion in previous research on the BF and MCI [9,12,46] and VH [7], as well as LEDD,

DA (yes/no), and ACB (yes/no) given their potential contribution to MCI and VH symptoms in

PD. Separate binary logistic regressions were conducted where the outcome variable was

cognitive status (MCI/Intact cognition) or VH status (noVH/VH), followed by a multinomial

regression where the outcome was a combination of these factors (i.e., MCI-VH, MCI-noVH,

Intact cognition-noVH), excluding the rare Intact cognition-VH. From the latter analysis, three

pairwise contrasts were examined. Statistical threshold for the Total BF variable was set at p

<.05 corrected for five comparisons using the Benjamini-Hochberg FDR method. Following

these main analyses, similar exploratory logistic regressions were conducted separately for

specific BF ROIs (Ch1-2, Ch3, Ch4 and Ch4p). Statistical threshold for each ROI was set at p

<.05 corrected for the four ROIs within each group comparison analysis using the FDR method.

Logistic regression assumptions were examined using appropriate statistical tests (i.e., Variance

Inflation Factors, Box-Tidwell procedure, Cook's distance). Of note, our statistical approach

deviates from our pre-registered plan due to sample characteristics, reviewers' feedback, and

statistical considerations. Detailed explanations are provided in Supplementary Materials.

Data sharing

All data are part of the patients' clinical charts, and patients have not provided consent to

share their data publicly as this is a retrospective study.

RESULTS

Participant characteristics

Patient characteristics and related statistics are presented in Tables 1 and 2 according to

cognitive status and VH status, and in Table S2 for the combination of symptoms. Overall,

61.1% of patients presented with PD-MCI and 25.3% with VH. These symptoms co-occurred in

20.6% of the sample, and few participants presented with VH without MCI (4.7%). There were

no differences between cognitive or VH status groups for age, education, disease duration,

LEDD, ACB, or MDS-UPDRS-III OFF scores. The VH group had a higher proportion of people

taking DA than the noVH group. The MCI group had higher MDS-UPDRS-III ON scores and

were less responsive to levodopa than the Intact cognition group, but did not differ with respect

to DA.

Total basal forebrain volume, MCI, and VH

Univariate group comparisons of BF volumes are presented in Tables 1, 2, and S2

(uncorrected). Given the potential contribution of confound variables (i.e., age, sex, LEDD, DA,

and ACB), the relationships between Total BF volume and MCI, VH and their co-occurrence

were assessed using logistic regressions. All models met statistical assumptions. OR with 95%CI

are depicted in Figure 1a for Total BF volume and covariates. Results show Total BF volume to

be negatively associated with the likelihood of MCI ($p = .004$; FDR-corr. $p = .02$), but not that of

VH (p = .13). Null findings for VH status were replicated after excluding individuals without VH

treated with antipsychotic medication (n=16; p = .12). Total BF volume was also negatively

associated with the likelihood of co-occurring MCI and VH relative to neither symptom (p =

.006; FDR-corr. p = .02). However, no significant relationship was observed in the likelihood of

MCI in non-hallucinators (p = .08), or of VH in patients with MCI (p = .18). These results

suggest that smaller BF volume is associated with MCI, but not VH when investigated in

isolation. However, when considering both symptoms, smaller BF volume shows a modest

relationship with the co-occurrence of MCI and VH relative to neither symptom. Despite the

significant effect for MCI when VH is not considered, Total BF volume did not increase the

likelihood of MCI in the absence of VH.

Regional basal forebrain nuclei, MCI and VH

To examine the relationship between the BF, VH and MCI further, similar exploratory

analyses were conducted with the four regional BF nuclei (Ch1-2, Ch3, Ch4, Ch4p). Univariate

group comparisons of these volumes are presented in Tables 1, 2, and S2 (uncorrected), and

separate logistic regressions accounting for potential confounds were conducted. These analyses

met statistical assumptions except for Ch3 in analyses involving VH, and these results should be

interpreted with caution. OR and 95%CI for each ROI across analyses are depicted in Figure 1b.

In models investigating symptoms in isolation, both Ch1-2 and Ch4 volumes were negatively

related to the likelihood of MCI (Ch1-2: p = .01; FDR-corr. p = .03; Ch4: p = .007; FDR-corr. p

= .03). However, other nuclei did not show significant relationships with MCI (Ch3: p = .08;

Ch4p: p = .26). In keeping with null findings obtained with the Total BF volume, regional BF

volumes were not significantly associated with the likelihood of VH ($p \geq$ .08). In models

considering symptoms' co-occurrence, only Ch4 volume showed a statistically significant

relationship with MCI-VH relative to Intact cognition-noVH ($p = 007$; FDR-corr. $p = .03$).

Volumes in other ROIs in this group contrast and all ROIs in other group contrasts did not reach

statistical significance ($p \geq .07$, or FDR-corr. $p \geq .14$). Together, these results suggest that

reduced Ch1-2 and Ch4 volumes relate to MCI when VH is not considered, and only reduced

Ch4 volume relates significantly to the co-occurrence of MCI and VH relative to neither

symptom.

DISCUSSION

Our study is novel in that we examine the relationships between BF volumes, MCI and

VH in a single cohort of individuals with long disease duration, and hence test the cholinergic

phenotype hypothesis by bridging the literature linking the BF to each type of symptom

separately. When examining symptom types separately and accounting for demographic

variables and pharmacotherapy, we show that smaller Total BF volumes are modestly associated

with higher odds of being diagnosed with MCI, but not VH. Smaller Ch4 and Ch1-2 are also

modestly associated with higher odds of PD-MCI when VH symptoms are not considered. When

both symptom types are considered, smaller Total BF and Ch4 volumes modestly relate to the

co-occurrence of MCI and VH relative to neither symptom, and no other associations reached

statistical threshold. Together, our results suggest that BF volumes, and particularly Ch4

volumes, are related to MCI, and this relationship is most robust when VH and MCI co-occur,

which is consistent with the cholinergic phenotype hypothesis [4]. Ch1-2 volumes also appear to

relate to MCI when VH status is not considered, which is interesting given its projection to

temporal lobe regions, but this effect was not evident when considering both symptom types.

While we are first to examine both VH and MCI concurrently, our findings implicating

the Total BF and Ch4 in MCI and in the co-occurrence of MCI and VH are consistent with the

literature investigating these symptoms (in isolation). Although variability in findings across

studies is noted, Total BF or Ch4 volume loss was previously shown to modestly relate to, or

predict, each symptom in early PD [7–9] as well as performance on general cognition, memory,

attention, executive functions, and visuospatial functions tests [9,12,46,47]. While the Total BF,

including Ch4, does not exclusively comprise of cortically-projecting cholinergic neurons [43],

recent evidence using more direct measurements of cortical acetylcholine (F-FEOBV PET) in

PD demonstrates reductions in patients with cognitive decline [4], or in PD-VH [48].

Importantly, significant relationships were demonstrated between BF volumes and acetylcholine

levels measured by PET across cortical and subcortical regions in PD [48,49], and BF volume

was shown to mediate the relationship between acetylcholine levels and memory in the lateral

neocortex and hippocampus [47]. Together, this evidence provides further support for the

cholinergic hypothesis.

As for other BF nuclei, we found a modest relationship between Ch1-2 volume and the

likelihood of PD-MCI, but found no significant effects for Ch3 or Ch4p. Only a few studies in

PD report findings in these nuclei. One study showed Ch4p was not predictive of developing PD-

MCI [12]. Studies investigating Ch1-2 or Ch1-2-3 volumes also yielded null findings when

comparing PD-MCI or PD-VH to their cognitively intact or non-hallucinator counterparts [7,9]

or PD patients to controls [46,49]. In contrast, one study found Ch1-2-3 volumes were smaller in

de novo PD patients compared to controls and were correlated with visuospatial abilities and

attention, but not memory [12]. The latter is surprising as the hippocampus is a major projection

area of Ch1-2 and is critical to memory functioning. However, another study demonstrated a

significant and specific relationship between Ch1-2 volume and visual memory in PD, which

was mediated by hippocampal volumes [46]. The variability in findings between studies,

including the present one, may be due to methodological differences in imaging analyses

pipeline, diagnostic criteria, or patient characteristics including disease duration. Notably,

volume loss in BF nuclei could follow a similar posterior to anterior pattern of progression as

that seen in the Alzheimer's disease spectrum [40], and thus Ch1-2 nuclei may be less affected at

the early stages of PD.

Our study has several limitations, which may be addressed in future research. PD patients

in our sample were being considered for DBS due to dyskinesia and motor fluctuations.

Therefore, our findings may not generalize to the entire PD population, including patients who

would be ineligible for DBS due to older age, presence of dementia, or severe balance problems.

Despite this, the proportion of patients from our cohort presenting with concurrent VH and PD-

MCI (21%) is similar to that reported in broader PD groups in a systematic review (28%) [1].

Furthermore, other studies investigating BF integrity in PD-MCI or as a predictor of future PD-

VH leveraged data from a similar clinical group, albeit without accounting for medications in

their statistical models [10,12].

Second, we relied on patient self-report during the clinical neuropsychology interview to

ascertain the presence of VH and then coded these responses on a validated PD-specific scale.

While we recognize that there are several standardized methods to assess VH in PD, they are not

without limitations [50]. Gathering information from a semi-structured interview enables patients

to describe their experience in their own words and allows clinicians to ask for elaboration. We

also recognize that most patients with VH had minor hallucinations/illusions, and stronger

relationships with BF volumes may be found in in more severe forms. However, findings

showing relationships between Ch4 and future VH were also based on minor VH measured on

the same MDS-UPDRS item [7].

Third, because MRI scans were acquired as part of the clinical care, variability in

acquisition parameters may have introduced measurement error despite resampling to a common

isometric voxel size. However, voxel size did not differ between groups, and thus, did not

introduce a systematic bias (Table S4). Differences in results across regional BF may also reflect

differences in the sizes of the original ROIs (Ch4>Ch1-2>Ch3=Ch4p), although measures were

z-transformed. We deviated from our pre-registered analyses plan due to sample characteristics,

statistical assumptions and reviewers' suggestions (supplementary materials). We also cannot

comment on the degree of atrophy given the absence of a healthy control group. Lastly, while

VBM imaging methodology can provide insights based on group data, it is not amenable for use

at the individual level. To our knowledge, no in-vivo technique to date provides the necessary

precision to measure BF integrity for clinical use.

In conclusion, our findings support the notion that PD is a heterogeneous disease with

individual differences not only in the degree of dopaminergic, but also of cholinergic

dysfunction. Our study is in line with the cholinergic phenotype [4] as the co-occurrence of MCI

and VH is associated with greater BF volume loss, particularly in Ch4. Future research is needed

to examine the prevalence of the co-occurrence of other symptoms associated with this

phenotype and relation to the integrity of the cholinergic system. This knowledge will contribute

to the development of a unified method of assessing cholinergic compromise in PD, which

would benefit the design of clinical trials targeting the cholinergic system and treatment planning

in clinical care.

ACKNOWLEDGMENTS

We thank Bianca Iddiols and Megan Vaziri for their help with data extraction and coding.

AUTHORS' ROLES

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical analysis: A.

Design, B. Execution, C. Review and critique; (3) Manuscript preparation: A. Writing of the first

draft, B. Review and critique.

S.A.: 1A, 1B, 1C, 2A, 2B, 3A, 3B

V.M.: 1C, 3B

M.S.: 1C, 2C, 3C

B.K.: 1C, 3B.

T.W.S.: 1A, 2C, 3B

A.C.R.: 1A, 2C, 3B

M.C.: 1A. 1B, 1C, 2A, 2B, 2C, 3A, 3B

DISCLOSURES

Funding Sources and Conflict of Interest: This work was supported by the Canadian Institutes

of Health Research (CIHR; FRN 156447 & 162197) and UHN Collaborative Academic Practice.

The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the previous 12 months: M.C. and M.S. received funding from the

Michael J. Fox Foundation for Parkinson's Research; S.A. receives funding from the University

of Toronto and UHN; A.C.R. received funding from CIHR, SSHRC, the CAMH Foundation, and

the University of Toronto, and received a honorarium from the University Institute of Mental

Health in Montreal; T.W.S. received funding from the Alzheimer's Society of Canada, CIHR,

NSERC, Canada Foundation for Innovation, Western University, and the Ontario Ministry of

Colleges and Universities; and BK and VM receive funding from CIHR.

Ethical Compliance Statement: This study was approved by the Research Ethics Board at

University Health Network. Informed consent was not necessary given the retrospective, clinical

chart review design of the study. We confirm that we have read the Journal's position on issues

involved in ethical publication and affirm that this work is consistent with those guidelines.

References

[1] Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson's
disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol
Med 2019;49:2342–53. https://doi.org/10.1017/S0033291718003161.

[2] Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney Multicenter Study of
Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorders
2008;23:837–44. https://doi.org/10.1002/mds.21956.

[3] Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign
hallucinations" in Parkinson disease. Arch Neurol 2006;63:713–6.
https://doi.org/10.1001/archneur.63.5.713.

[4] Pasquini J, Brooks DJ, Pavese N. The Cholinergic Brain in Parkinson's Disease. Mov Disord
Clin Pract 2021;8:1012–26. https://doi.org/10.1002/mdc3.13319.

[5] Newman EL, Gupta K, Climer JR, Monaghan CK, Hasselmo ME. Cholinergic modulation of
cognitive processing: Insights drawn from computational models. Front Behav Neurosci
2012;6:1–19. https://doi.org/10.3389/fnbeh.2012.00024.

[6] Slater NM, Melzer TR, Myall DJ, Anderson TJ, Dalrymple-Alford JC. Cholinergic Basal
Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic
Resonance Imaging Evidence. Mov Disord 2024;39:2155–72.
https://doi.org/10.1002/mds.30023.

[7] Barrett MJ, Blair JC, Sperling SA, Smolkin ME, Druzgal TJ. Baseline symptoms and basal
forebrain volume predict future psychosis in early Parkinson disease. Neurology
2018;90:e1618–26. https://doi.org/10.1212/WNL.0000000000005421.

[8] Schulz J, Pagano G, Fernández Bonfante JA, Wilson H, Politis M. Nucleus basalis of
Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease.
Brain 2018;141:1501–16. https://doi.org/10.1093/brain/awy072.

[9] Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis GK, et al. In vivo
cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's
disease. Brain 2018;141:165–76. https://doi.org/10.1093/brain/awx310.

[10] Hepp DH, Foncke EMJ, Berendse HW, Wassenaar TM, Olde Dubbelink KTE, Groenewegen
HJ, et al. Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson's disease
patients with visual hallucinations. Sci Rep 2017;7:1–10. https://doi.org/10.1038/s41598-
017-10146-y.

[11] Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RKB, Gentleman SM.
Dementia and visual hallucinations associated with limbic pathology in Parkinson's
disease. Parkinsonism Relat Disord 2009;15:196–204.
https://doi.org/10.1016/j.parkreldis.2008.05.007.

[12]   Barrett MJ, Sperling SA, Blair JC, Freeman CS, Flanigan JL, Smolkin ME, et al. Lower
volume, more impairment: reduced cholinergic basal forebrain grey matter density is
associated with impaired cognition in Parkinson disease. J Neurol Neurosurg Psychiatry
2019;90:1251–6. https://doi.org/10.1136/jnnp-2019-320450.

[13]   Pereira JB, Hall S, Jalakas M, Grothe MJ, Strandberg O, Stomrud E, et al. Longitudinal
degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
Neurobiol Dis 2020;139:104831. https://doi.org/10.1016/j.nbd.2020.104831.

[14]   Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R. Dopamine overdose
hypothesis: Evidence and clinical implications. Movement Disorders 2013;28:1920–9.
https://doi.org/10.1002/mds.25687.

[15]   Connolly BS, Lang AE. Pharmacological Treatment of Parkinson Disease. JAMA
2014;311:1670–83. https://doi.org/10.1001/jama.2014.3654.

[16]   Dave S, Weintraub D, Aarsland D, Ffytche DH. Drug and Disease Effects in Parkinson's
Psychosis: Revisiting the Role of Dopamine. Mov Disord Clin Pract 2020;7:32–6.
https://doi.org/10.1002/mdc3.12851.

[17]   Beck A, Steer R, Brown G. BDI-II: Beck Depression Inventory Manual. 2nd ed. San Antonio:
Psychological Corporation; 1996.

[18]   Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and
validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res
1982;17:37–49. https://doi.org/10.1016/0022-3956(82)90033-4.

[19]   Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic
criteria for dementia associated with Parkinson's disease. Movement Disorders
2007;22:1689–707. https://doi.org/10.1002/mds.21507.

[20]   McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis
and management of dementia with Lewy bodies: Fourth consensus report of the DLB
Consortium. Neurology 2017;89:88–100.
https://doi.org/10.1212/WNL.0000000000004058.

[21]   Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic
criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society
Task Force guidelines. Movement Disorders 2012;27:349–56.
https://doi.org/10.1002/mds.24893.

[22]   Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa
dose equivalency reporting in Parkinson's disease. Movement Disorders 2010;25:2649–
53. https://doi.org/10.1002/mds.23429.

[23]   Campbell NL, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the
anticholinergic cognitive burden scale. J Am Geriatr Soc 2013;61:S142–3.
https://doi.org/10.1111/jgs.12263.

[24]   Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al.
443   Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating
444   Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement
445   Disorders 2008;23:2129–70. https://doi.org/10.1002/mds.22340.

446   [25]   Fahn S;, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating
447   Scale. Recent Developments in Parkinson's Disease 1987;2:153–63.

448   [26]   Hentz JG, Mehta SH, Shill HA, Driver-Dunckley E, Beach TG, Adler CH. Simplified
449   conversion method for unified Parkinson's disease rating scale motor examinations.
450   Movement Disorders 2015;30:1967–70. https://doi.org/10.1002/mds.26435.

451   [27]   Calamia M, Markon K, Denburg NL, Tranel D. Developing a short form of Benton's
452   Judgment of Line Orientation Test: an item response theory approach. Clin Neuropsychol
453   2011;25:670–84. https://doi.org/10.1080/13854046.2011.564209.

454   [28]   Warrington EK, James M. The visual object and space perception battery. Bury St.
455   Edmunds, England: Thames Valley Test Company; 1991.

456   [29]   Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial. Odessa, FL:
457   Psychological Assessment Records; 1991.

458   [30]   Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test-2nd edition. Philadelphia,
459   PA: Lippincott Williams & Wilkins; 2001.

460   [31]   Wechsler D. WASI: Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The
461   Psychological Corporation; 1999.

462   [32]   Wechsler D. WASI-II: Wechsler Abbreviated Scale of Intelligence - second edition. San
463   Antonio, TX: The Psychological Corporation; 2011.

464   [33]   Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System. San Antonio, TX:
465   The Psychological Corporation; 2001.

466   [34]   Delis DC, Kramer JH, Kaplan E, Ober B. California Verbal Learning Test - Second edition.
467   San Antonio, TX: The Psychological Corporation; 2000.

468   [35]   Wechsler D. Wechsler Memory Scale (WMS-III). San Antonio, TX: The Psychological
469   Corporation; 1997.

470   [36]   Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded
471   Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African
472   American and Caucasian adults, professional manual. Odessa, FL: Psychological
473   Assessment Records; 2004.

474   [37]   Heaton RK, Chelune G, Talley J, Kay GG, Curtiss G. Wisconsin Card Sorting Test. Odessa, FL:
475   Psychological Assessment Records; 1993.

476   [38]   Taylor AE, Saint-Cyr JA, Lang AE. Memory and learning in early Parkinson's disease:
477   Evidence for a "frontal lobe syndrome." Brain Cogn 1990;13:211–32.
478   https://doi.org/10.1016/0278-2626(90)90051-O.

479   [39]   Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC:
480   Advancing the automatic prediction of image quality in MRI from unseen sites. PLoS One
481   2017;12:e0184661. https://doi.org/10.1371/journal.pone.0184661.

482   [40]   Schmitz TW, Spreng RN, Alzheimer's Disease Neuroimaging Initiative. Basal forebrain
483   degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat
484   Commun 2016;7:13249. https://doi.org/10.1038/ncomms13249.

485   [41]   Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN. Longitudinal Alzheimer's
486   Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections.
487   Cell Rep 2018;24:38–46. https://doi.org/10.1016/j.celrep.2018.06.001.

488   [42]   Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–
489   113. https://doi.org/10.1016/j.neuroimage.2007.07.007.

490   [43]   Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic
491   probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage
492   2008;42:1127–41. https://doi.org/10.1016/j.neuroimage.2008.05.055.

493   [44]   Wang Y, Zhan M, Roebroeck A, De Weerd P, Kashyap S, Roberts MJ. Inconsistencies in
494   atlas-based volumetric measures of the human nucleus basalis of Meynert: A need for
495   high-resolution alternatives. Neuroimage 2022;259:119421.
496   https://doi.org/10.1016/j.neuroimage.2022.119421.

497   [45]   Wang J, Hill-Jarrett T, Buto P, Pederson A, Sims KD, Zimmerman SC, et al. Comparison of
498   approaches to control for intracranial volume in research on the association of brain
499   volumes with cognitive outcomes. Hum Brain Mapp 2024;45:e26633.
500   https://doi.org/10.1002/hbm.26633.

501   [46]   Berlot R, Pirtošek Z, Brezovar S, Koritnik B, Teipel SJ, Grothe MJ, et al. Cholinergic basal
502   forebrain and hippocampal structure influence visuospatial memory in Parkinson's
503   disease. Brain Imaging Behav 2022;16:118–29. https://doi.org/10.1007/s11682-021-
504   00481-0.

505   [47]   Crowley SJ, Kanel P, Roytman S, Bohnen NI, Hampstead BM. Basal forebrain integrity,
506   cholinergic innervation and cognition in idiopathic Parkinson's disease. Brain
507   2024;147:1799–808. https://doi.org/10.1093/brain/awad420.

508   [48]   d'Angremont E, van der Zee S, Slingerland S, Slomp AC, de Vries EFJ, van Laar T, et al.
509   Cholinergic deficiency in Parkinson's disease patients with visual hallucinations. Brain
510   2024;147:3370–8. https://doi.org/10.1093/brain/awae186.

511   [49]   Legault-Denis C, Aumont É, Onuska KM, Schmitz TW, Bussy A, Chakravarty M, et al.
512   Parkinson's disease CA2-CA3 hippocampal atrophy is accompanied by increased
513   cholinergic innervation in patients with normal cognition but not in patients with mild
514   cognitive impairment. Brain Imaging Behav 2024;18:783–93.
515   https://doi.org/10.1007/s11682-024-00872-z.

516   [50]   Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The psychosis
517   spectrum in Parkinson Disease. Nat Rev Neurol 2017;13:81–95.
518   https://doi.org/10.1038/nrneurol.2016.200.

521   **Table 1. Characteristics of the PD-Intact Cognition and PD-MCI groups**

	Intact Cognition n = 115	MCI n = 181	Statistics
Characteristics			
Female	30.4%	26.5%	$\chi^2 = 0.53$, $p = .47$, $OR = 0.83$, CI [0.49-1.38]
Age (years)	60.38 (7.77)	61.75 (7.41)	$U = 9319.5$, $p = .13$, $r = -.09$
Education (years)	14.62 (3.19)	14.12 (3.04)	$U = 9338.5$, $p = .13$, $r = -.09$
Disease duration (years)	9.24 (3.67)	10.18 (4.25)	$U = 9257.5$, $p = .11$, $r = -.09$
MDS-UPDRS-III ON	14.54 (8.99)	17.83 (10.05)	$U = 8090$, $p < .001$, $r = -.19$
MDS-UPDRS-III OFF[a]	37.45 (14.51)	40.00 (14.46)	$U = 8644.5$, $p = .07$, $r = -.11$
Levodopa response[a]	62.40 (16.48)	56.64 (16.63)	$U = 7754$, $p = .002$, $r = -.18$
Medications			
Total LEDD (mg)	1345.75 (607.34)	1430.70 (633.67)	$U = 11260$, $p = .24$, $r = -.07$
DA (yes)	53.0%	48.1%	$\chi^2 = 0.70$, $p = .40$, $OR = 0.82$, CI [0.51-1.31]
ACB ≥3	12.2%	18.2%	$\chi^2 = 1.93$, $p = .17$, $OR = 1.61$, CI [0.82-3.16]
Basal forebrain volumes (std)[b]			
Total BF	0.25 (0.94)	-0.15 (1.00)	$U = 8070$, $p = .001$, $r = -.19$
Ch1-2	0.23 (1.00)	-0.15 (0.97)	$U = 8364$, $p = .004$, $r = -.17$
Ch3	0.18 (1.02)	-0.11 (0.97)	$U = 9019$, $p = .05$, $r = -.11$
Ch4	0.22 (0.88)	-0.14 (1.04)	$U = 8229$, $p = .002$, $r = -.18$
Ch4p	0.09 (0.91)	-0.06 (1.05)	$U = 9453$, $p = .18$, $r = -.08$

Note. Data are presented as mean (SD), and statistics are uncorrected. MDS-UPDRS-III:

Movement Disorders Society—Unified Parkinson's Disease Rating Scale part 3; LEDD:

Levodopa Equivalent Daily Dose; DA: dopamine agonist; ACB: Anticholinergic Cognitive

Burden scale. Levodopa response = ((OFF–ON)/OFF*100%). CI are 95%. [a]Seven missing

scores. [b] Standardized residuals corrected for total intracranial volume.

Table 2. Characteristics of the PD-noVH and PD-VH groups

	No VH n = 221	VH n = 75	Statistics
Characteristics			
Female	30.8%	20.0%	$\chi^2 = 3.22$, $p = .07$, $OR = 0.56$, CI [0.30-1.06]
Age (years)	60.97 (7.68)	61.93 (7.24)	$U = 7600$, $p = .28$, $r = -.06$
Education (years)	14.44 (3.15)	13.93 (2.95)	$U = 7654$, $p = .32$, $r = -.06$
Disease duration (years)	9.56 (3.95)	10.57 (4.30)	$U = 7179$, $p = .08$, $r = -.10$
MDS-UPDRS-III ON	16.58 (10.1)	16.47 (8.78)	$U = 8204$, $p = .90$, $r = -.01$
MDS-UPDRS-III OFF[a]	38.78 (15.01)	39.71 (13.01)	$U = 7450$, $p = .36$, $r = -.05$
Levodopa response[a]	58.49 (17.69)	59.91 (13.86)	$U = 7717.5$, $p = .62$, $R = -.03$
Medications			
Total LEDD, mg	1365.67 (622.87)	1492.06 (621.54)	$U = 7384$, $p = .16$, $r = -.08$
DA (yes)	45.7%	62.7%	$\chi^2 = 6.45$, $p = .01$, $OR = 1.99$, CI [1.17-3.41]
ACB ≥ 3	17.2%	12.0%	$\chi^2 = 1.13$, $p = .29$, $OR = 0.66$, CI [0.30-1.43]
Basal forebrain volumes (std)[b]			
Total BF	0.06 (1.01)	-0.19 (0.92)	$U = 6924$, $p = .03$, $r = -.12$
Ch1-2	0.02 (1.04)	-0.06 (0.87)	$U = 7943$, $p = .60$, $r = -.03$
Ch3	0.03 (1.04)	-0.08 (0.85)	$U = 7756$, $p = .41$, $r = -.05$
Ch4	0.07 (1.00)	-0.21 (0.96)	$U = 6683$, $p = .01$, $r = -.15$
Ch4p	0.06 (0.99)	-0.18 (1.00)	$U = 7013$, $p = .05$, $r = -.12$

Note. Data are presented as mean (SD) and statistics are uncorrected. MDS-UPDRS-III:

Movement Disorders Society—Unified Parkinson's Disease Rating Scale part 3; LEDD:

Levodopa Equivalent Daily Dose; DA: dopamine agonist; ACB: Anticholinergic Cognitive

Burden scale. Levodopa response = ((OFF–ON)/OFF*100%). CI are 95%. [a]Seven missing

scores. [b] Standardized residuals corrected for total intracranial volume.

Figure captions

Figure 1. Comparisons of basal forebrain volumes across groups as a function of cognitive

and VH status

Note. (a) OR and 95% CI of Total BF standardized residuals (corrected for TIV) after covarying

age, sex, total levodopa equivalent daily dose (LEDD), dopamine agonist (DA, yes/no), and

anticholinergic cognitive burden score (ACB≥3) in logistic regressions. (b) OR and 95% CI of

regional BF volumes derived from independent logistic regressions after covarying age, sex,

LEDD, DA, and ACB.

Supplementary materials

Table S1. Patients' characteristics across combined cognitive and VH statuses

Table S2. Visual hallucination severity and types

Table S3. MCI subtypes and cognitive domains affected

Table S4. MRI acquisition parameters

Transparency and openness: Description of deviations from the pre-registered methodology.

STROBE Checklist